Payment overview · 2025
General Payments
$758.08
29 reported records · 13 companies
Healthcare provider profile · identity verified
Mina Sameh Sobhy Soliman, MD
Allopathic & Osteopathic Physicians|Family Medicine · YUCAIPA, CA · NPI 1457730392
Verified facts
What the public records show
CMS Open Payments records show Mina Sameh Sobhy Soliman, MD received $758.08 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.87 | 22.7% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $131.66 | 17.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.34 | 11.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.15 | 9.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.39 | 9.7% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $64.58 | 8.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.06 | 3.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.80 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.56 | 3.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.55 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.04 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.44 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.64 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $758.08 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $157.91 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $88.60 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $84.34 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $74.64 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $74.15 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $74.15 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $74.15 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $73.39 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $64.58 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.12 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.88 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
94 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 626 | 207 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 143 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 366 | 124 |
| Losartan Potassium | Losartan Potassium | 359 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 317 | 105 |
| Lisinopril | Lisinopril | 296 | 97 |
| Gabapentin | Gabapentin | 247 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 73 |
| Omeprazole | Omeprazole | 209 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 74 |
| Metformin Hcl | Metformin Hcl | 184 | 59 |
| Alendronate Sodium | Alendronate Sodium | 176 | 40 |
| Metformin Hcl Er | Metformin Hcl | 174 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 57 |
| Trazodone Hcl | Trazodone Hcl | 153 | 47 |
| Simvastatin | Simvastatin | 126 | 44 |
| Finasteride | Finasteride | 101 | 32 |
| Carvedilol | Carvedilol | 99 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 95 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 16 |
| Famotidine | Famotidine | 90 | 32 |
| Benazepril Hcl | Benazepril Hcl | 89 | 25 |
| Eliquis | Apixaban | 88 | 24 |
| Farxiga | Dapagliflozin Propanediol | 88 | 22 |
| Spironolactone | Spironolactone | 88 | 31 |
| Allopurinol | Allopurinol | 86 | 31 |
| Jardiance | Empagliflozin | 85 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 27 |
| Furosemide | Furosemide | 74 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 25 |
| Baclofen | Baclofen | 71 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 19 |
| Tramadol Hcl | Tramadol Hcl | 67 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 22 |
| Alprazolam | Alprazolam | 60 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 59 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 22 |
| Ibuprofen | Ibuprofen | 58 | 33 |
| Sertraline Hcl | Sertraline Hcl | 58 | 16 |
| Atenolol | Atenolol | 55 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 15 |
| Januvia | Sitagliptin Phosphate | 54 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 12 |
| Ozempic | Semaglutide | 52 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 11 |
| Potassium Chloride | Potassium Chloride | 51 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 18 |
| Diclofenac Sodium Er | Diclofenac Sodium | 46 | 16 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 45 | 12 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 11 |
| Meloxicam | Meloxicam | 41 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Glipizide | Glipizide | 39 | 13 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 13 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 14 |
| Xarelto | Rivaroxaban | 37 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 11 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 12 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | 11 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Prednisone | Prednisone | 23 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 12 |
| Lorazepam | Lorazepam | 22 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Constulose | Lactulose | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 11 |
| Estradiol | Estradiol | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Menest | Estrogens,esterified | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $758.08 · 29 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, INGREZZA, JARDIANCE, Kerendia, Korlym, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Veozah | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error